-
Mashup Score: 0Novartis: launch of Morphosys drug by could be 2027 or later - 2 hour(s) ago
Novartis’ CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Health Rounds: Blood thinners don't benefit low-risk patients with atrial fibrillation - 3 hour(s) ago
Hello Health Rounds Readers! Today we feature three more studies that were presented at one of the year’s most important heart meetings, the American Heart Association Scientific Sessions that wrapped up this week in Chicago.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Hello Health Rounds Readers! Today we feature three more studies that were presented at one of the year's most important heart meetings, the American Heart Association Scientific Sessions that wrapped up this week in Chicago. https://t.co/alPjQOjJ2E https://t.co/alPjQOjJ2E
-
-
Mashup Score: 0Novartis raises annual sales guidance until 2028 - 4 hour(s) ago
Novartis on Thursday raised its medium-term sales guidance to 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Novartis on Thursday raised its medium-term sales guidance to 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions. https://t.co/eDdqm8rxqM https://t.co/eDdqm8rxqM
-
-
Mashup Score: 4
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals’ drug for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug for the treatment of a type of biliary tract cancer, the company said on Wednesday. https://t.co/oAa5VctnAd https://t.co/oAa5VctnAd
-
-
Mashup Score: 1Health Rounds: Blood thinners don't benefit low-risk patients with atrial fibrillation - 8 hour(s) ago
Hello Health Rounds Readers! Today we feature three more studies that were presented at one of the year’s most important heart meetings, the American Heart Association Scientific Sessions that wrapped up this week in Chicago.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Hello Health Rounds Readers! Today we feature three more studies that were presented at one of the year's most important heart meetings, the American Heart Association Scientific Sessions that wrapped up this week in Chicago. https://t.co/RdUXHLFrs0 https://t.co/RdUXHLFrs0
-
-
Mashup Score: 2
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals’ drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday. https://t.co/okk46DsgNp https://t.co/okk46DsgNp
-
-
Mashup Score: 0Health Rounds: Blood thinners don't benefit low-risk patients with atrial fibrillation - 12 hour(s) ago
Hello Health Rounds Readers! Today we feature three more studies that were presented at one of the year’s most important heart meetings, the American Heart Association Scientific Sessions that wrapped up this week in Chicago.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Hello Health Rounds Readers! Today we feature three more studies that were presented at one of the year's most important heart meetings, the American Heart Association Scientific Sessions that wrapped up this week in Chicago. https://t.co/3qI0bcmfyg https://t.co/3qI0bcmfyg
-
-
Mashup Score: 0
Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington’s disease, a rare neurological disorder.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare neurological disorder. https://t.co/zjcNVHkE2D https://t.co/zjcNVHkE2D
-
-
Mashup Score: 1Pfizer names oncology head Chris Boshoff as R&D chief - 14 hour(s) ago
Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce profitable new drugs.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce profitable new drugs. https://t.co/344mbZLZoN https://t.co/344mbZLZoN
-
-
Mashup Score: 2
About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. https://t.co/5pJFGQHMdy https://t.co/5pJFGQHMdy
-
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data. https://t.co/boJX8h6kRF https://t.co/boJX8h6kRF